Registry of Lobbyists

Registration - In-house Corporation

AVENTIS PASTEUR / DONALD MCKIBBIN, DIRECTOR, PUBLIC & INDUSTRY RELATIONS

Registration Information

In-house Corporation name: AVENTIS PASTEUR
Responsible Officer Name: DONALD MCKIBBIN, DIRECTOR, PUBLIC & INDUSTRY RELATIONS 
Initial registration start date: 1997-03-10
Registration status: Inactive
Registration Number: 780031-11791

Version 3 of 6 (1999-02-11 to 2000-01-31)

Version 3 of 6 (1999-02-11 to 2000-01-31) was submitted prior to the Lobbying Act coming into force on July 2, 2008. Due to different information requirements at that time, the registration is presented in the following format.

A. Information about Lobbyist and Corporation

Corporation: AVENTIS PASTEUR
CONNAUGHT CAMPUS, 1755 STEELES AVE WEST
TORONTO, ON  M2R 3T4
Canada
Telephone number: 416-667-2694
Fax number: 416-667-2865  
Responsible officer name and position during the period of this registration: DONALD S MCKIBBIN, DIRECTOR, PUBLIC & INDUSTRY RELATIONS  
Description of activities: PASTEUR MERIEUX CONNAUGHT IS THE WORLD'S LEADING PRODUCER OF VACCINES FOR HUMAN HEALTH AND A MEMBER OF THE RHONE-POULENC FAMILY OF COMPANIES. PASTEUR MERIEUX CONNAUGHT'S CANADIAN OPERATION IN TORONTO PRODUCES VACCINES AND IMMUNOTHERAPEUTIC PRODUCTS. PMC CANADA IS ALSO ONE OF THE MOST RESEARCH INTENSIVE BIOTECHNOLOGY COMPANIES IN THIS COUNTRY. RESEARCH PROJECTS CURRENTLY UNDERWAY INCLUDE:DEVELOPMENT OF GENETICALLY ENGINEERED HIV PSEUDOVIRION FOR TREATING AIDS PATIENTSIMPROVED, ACELLULAR VACCINE AGAINST PERTUSSIS (WHOOPING COUGH)POTENTIAL NEW VACCINE AGAINST THE RESPIRATORY SYNCITIAL VIRUS (CROUP)NEW COMBINED VACCINES THAT PROTECT AGAINST MANY DISEASES WITH ONE VACCINATIONORAL VACCINE DELIVERY THAT COULD ELIMINATE THE NEED FOR INJECTIONSA MAJOR RESEARCH PRIORITY IS THE DEVELOPMENT OF VACCINES AGAINST PATHOGENS RESPONSIBLE FOR SEVERAL TYPES OF HUMAN CANCERS. THIS PROGRAM INVOLVES MULTIPLE CANADIAN PARTNERS AND COULD REACH $360 MILLION OVER 10 YEARS.
 
Parent: The corporation is not a subsidiary of any other parent corporations.
Coalition The corporation is not a member of a coalition.
Subsidiary: The corporation does not have any subsidiaries that could be affected by the outcome of the undertaking.
Other direct interests The corporation's activities are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
 
Was the corporation funded in whole or in part by any domestic or foreign government institution in the last completed financial year? No
 

B. Lobbying Activity Information

Federal departments or organizations which have been or will be communicated with during the course of the undertaking: Canadian International Development Agency (CIDA), Competition Tribunal (CT), Foreign Affairs and International Trade Canada (DFAITC), Health Canada (HC), Industry Canada, INVESTMENT REVIEW AGENCY, National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB)
Communication techniques that have been used or are expected to be used in the course of the undertaking:
Meetings, Telephone calls, Written communications, whether in hard copy or electronic format
 
Subject Matter: Areas of Concern: Consumer Issues, Government Procurement, Health, Industry, Intellectual Property, Internal Trade, International Trade, Science and Technology
 
Subject Matter: Particulars: ANY FURTHER REVIEW OF DRUG PATENT LEGISLATION 9 FORMERLY BILL C-91);TECHNOLOGY PARTNERSHIPS CANADA PROGRAM;BIOTECHNOLOGY - VACCINE MANUFACTURING;SCIENTIFIC EDUCATION; STUDENT BIOTECHNOLOGY PROGRAMS; HUMAN RESOURCES.




Date Modified: